Rimonabant for prevention of cardiovascular events (CRESCENDO) : a randomised, multicentre, placebo-controlled trial.
(2010) The Lancet — Vol. 376, n° 9740, p. 517-523 (2010)
Files
pdfdocument.pdf
Restricted Access - Adobe PDF
- 316.74 KB
Details
- Authors
Thissen, Jean-Paul 
- Abstract
- Blockade of the endocannabinoid receptor reduces obesity and improves metabolic abnormalities such as triglycerides, HDL cholesterol, and fasting blood glucose. We assessed whether rimonabant would improve major vascular event-free survival.
- Affiliations
Citations
Topol, E. J., Bousser, M.-G., Fox, K. A. A., Creager, M. A., Despres, J.-P., Easton, J. D., Hamm, C. W., Montalescot, G., CRESCENDO Investigators., Steg, P. G., Pearson, T. A., Cohen, E., Gaudin, C., Job, B., Murphy, J. H., & Bhatt, D. L. (2010). Rimonabant for prevention of cardiovascular events (CRESCENDO) : a randomised, multicentre, placebo-controlled trial. The Lancet, 376(9740), 517-523. https://doi.org/10.1016/S0140-6736(10)60935-X (Original work published 2010)